This study is looking at how well a combination of standard chemotherapy drugs—Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone—works for people with previously untreated diffuse large B cell lymphoma (DLBCL). Researchers want to see if they can use PET scans and a blood test called circulating tumor DNA (ctDNA) to predict how well treatment is working and to identify markers of treatment failure. The study aims to enroll 40 participants aged 18 or older who have limited stage DLBCL. The main goal is to see how well the PET scan results match the ctDNA levels after 5 years, to help guide future treatments. The current recruitment status is unclear.

Study design

This is an interventional study with a planned enrollment of 40 participants. It is designed to evaluate the correlation between PET scans and ctDNA in patients with early stage DLBCL.

What's involved

Participants will receive standard chemoimmunotherapy and radiation. Blood tests for ctDNA will be taken at diagnosis and at specific times after treatment is complete.

Compensation

Not stated in the trial record.

Follow-up

The primary endpoint is measured at 5 years, suggesting a follow-up period of at least 5 years after treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.